Success is when the time to access an innovative treatment is reduced.
CT-SCOUTTM is a multi-device application aiming at facilitating the recruitment of patients in clinical studies...
It assists the investigational team in detecting the studies for which a patient is potentially eligible according to his/her current health conditions.
Transforms all physician into real time recruiters
On any device
Easy to use
1. An efficient algorithmic model
2. Real-time detection
studies registered (industrial & academic)
centers in various countries (Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, UK…)
They are so many drugs in development that it is extremely challenging to finds the way to one of them, as a patient or as a site, or to secure a high visibility on one of them for a Sponsor. CT-SCOUTTM and ToTem4me facilitate the match between the patients and the studies.
OF STUDIES FAIL TO MEET PATIENT RECRUITMENT DEADLINES
However, millions of patients visit clinical sites every day.
CT-SCOUT™ help investigators identify the ones that could benefit from a clinical study.
OF THE PATIENTS WOULD WELCOME THE OPPORTUNITY TO PARTICIPATE TO A CLINICAL STUDY
Patients have become actors of their treatment conditions.
ToTem4me help them identify potential opportunities through clinical studies.
OF THE PATIENTS ARE BEING OFFERED TO PARTICIPATE TO A CLINICAL STUDY
But 80% of patients would accept to participate t a clinical study.
CT-SCOUT™ contributes to increase the percentage of patients considered for clinical research.
WEEKS SET-UP TIME
No more than 2 weeks are required to get CT-SCOUT™
or ToTem4me deployed for a clinical study
Assist investigational teams in their clinical research activities
Shorten clinical trials by boosting detection of patients potentially eligible to clinical trials.
Allow patients’ earlier access to innovative and life-saving treatment.
May 22, 2023
Wednesday may 24 TELEMEDICINE TECHNOLOGIES will be present at SantExpo on the OVHcloud stand as a partner of the “Open Trusted Cloud” program. Our president Yoani Matsakis will be representing Telemedicine Technologies, and wil intervene next to Mathieu Godart, CTO and co-founder of SÊMEIA and Emmanuel MEYRIEUX, Client Security manager at OVHcloud. Throughout the day you […]
May 22, 2023
Fierce Biotech The FDA seems to be satisfied that Pfizer’s RSV vaccine is safe and effective for administration in pregnant women to protect infants from severe disease. The agency’s confidence was revealed in briefing documents filed ahead of an advisory committee meeting set for Thursday. The Vaccines and Related Biological Products Advisory Committee will consider […]
May 22, 2023
Trial Site News The World Health Organisation (WHO) decided Thursday May 4, 2023, to end the COVID-19 public health emergency of international concern (PHEIC). TrialSite cautions that this is a provisional (temporary) status while WHO considers its forward-looking options (2023-2025). Importantly, in “The COVID-19 Emergency is Over, Sort of,” TrialSite reports that in America some […]